Multiple strategies enhance the efficacy of MSCs transplantation for spinal cord injury

Pang, Qi-Ming; Deng, Kua-Qian; Zhang, Meng; Wu, Xiang-Chong; Yang, Renqiang; Fu, Sheng-Ping; Lin, Feng-Qin; Zhang, Qian; Ao, Jun; Zhang, Tao

doi:10.1016/j.biopha.2022.114011

Cited by 11 publications

(7 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature predominantly emphasizes mesenchymal stem cells (MSCs) [ 62 ], monocytes [ 37 ], embryonic stem cells [ 45 ], and human-induced pluripotent stem cells [ 23 ]. The integration of stem cell therapy with hydrogel protocols finds applications in the repair of spinal cord injuries [ 100 , 101 ], osteoarthritis treatment [ 102 ], chronic diabetic wound healing [ 103 ], cardiovascular disease treatment [ 104 , 105 ], and hind limb ischemia treatment [ 106 ]. MSCs [ 107 ] emerge as a promising option due to their ease of isolation, robust proliferative capacity, immunomodulatory ability, and diverse differentiation potential [ 108 ].…”

Section: Discussionmentioning

confidence: 99%

Injectable hydrogel-based combination therapy for myocardial infarction: a systematic review and Meta-analysis of preclinical trials

Gao,

Liu,

Qin

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Introduction This study evaluates the effectiveness of a combined regimen involving injectable hydrogels for the treatment of experimental myocardial infarction. Patient concerns Myocardial infarction is an acute illness that negatively affects quality of life and increases mortality rates. Experimental models of myocardial infarction can aid in disease research by allowing for the development of therapies that effectively manage disease progression and promote tissue repair. Diagnosis Experimental animal models of myocardial infarction were established using the ligation method on the anterior descending branch of the left coronary artery (LAD). Interventions The efficacy of intracardiac injection of hydrogels, combined with cells, drugs, cytokines, extracellular vesicles, or nucleic acid therapies, was evaluated to assess the functional and morphological improvements in the post-infarction heart achieved through the combined hydrogel regimen. Outcomes A literature review was conducted using PubMed, Web of Science, Scopus, and Cochrane databases. A total of 83 papers, including studies on 1332 experimental animals (rats, mice, rabbits, sheep, and pigs), were included in the meta-analysis based on the inclusion and exclusion criteria. The overall effect size observed in the group receiving combined hydrogel therapy, compared to the group receiving hydrogel treatment alone, resulted in an ejection fraction (EF) improvement of 8.87% [95% confidence interval (CI): 7.53, 10.21] and a fractional shortening (FS) improvement of 6.31% [95% CI: 5.94, 6.67] in rat models, while in mice models, the improvements were 16.45% [95% CI: 11.29, 21.61] for EF and 5.68% [95% CI: 5.15, 6.22] for FS. The most significant improvements in EF (rats: MD = 9.63% [95% CI: 4.02, 15.23]; mice: MD = 23.93% [95% CI: 17.52, 30.84]) and FS (rats: MD = 8.55% [95% CI: 2.54, 14.56]; mice: MD = 5.68% [95% CI: 5.15, 6.22]) were observed when extracellular vesicle therapy was used. Although there have been significant results in large animal experiments, the number of studies conducted in this area is limited. Conclusion The present study demonstrates that combining hydrogel with other therapies effectively improves heart function and morphology. Further preclinical research using large animal models is necessary for additional study and validation. Graphical abstract

show abstract

Section: Discussionmentioning

confidence: 99%

Injectable hydrogel-based combination therapy for myocardial infarction: a systematic review and Meta-analysis of preclinical trials

Gao,

Liu,

Qin

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…However, the exact function of MSCs has not been clarified so far. MSCs are directly implanted into the lesion site, and the harsh environment after SCI severely reduces their survival 35 . Although many experiments have been conducted in vitro to culture MSCs for mechanistic studies 36 , 37 , exploring the mechanism of MSC therapy in SCI in vivo is still difficult.…”

Section: Discussionmentioning

confidence: 99%

Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury

Yang,

Cao,

et al. 2024

Theranostics

View full text Add to dashboard Cite

Rationale: Spinal cord injury (SCI) is an acute damage to the central nervous system that results in severe morbidity and permanent disability. Locally implanted scaffold systems with immobilized mesenchymal stem cells (MSCs) have been widely proven to promote locomotor function recovery in SCI rats; however, the underlying mechanism remains elusive. Methods and Results:In this study, we constructed a hyaluronic acid scaffold system (HA-MSC) to accelerate the adhesive growth of human MSCs and prolong their survival time in SCI rat lesions. MSCs regulate local immune responses by upregulating the expression of anti-inflammatory cytokines. Interestingly, the dramatically increased, but transient expression of interleukin 10 (IL-10) is found to be secreted by MSCs in the first week. Blocking the function of the initially produced IL-10 by the antibody completely abolished the neurological and behavioral recovery of SCI rats, indicating a core role of IL-10 in SCI therapy with HA-MSC implantation. Transcriptome analyses indicated that IL-10 selectively promotes the migration and cytokine secretion-associated programs of MSCs, which in turn helps MSCs exert their anti-inflammatory therapeutic effects. Conclusion: Our findings highlight a novel role of IL-10 in regulating MSC migration and cytokine secretion-associated programs, and determine the vital role of IL-10 in the domination of MSC treatment for spinal cord repair.

show abstract

“…Furthermore, MSCs secrete a variety of growth factors and cytokines that promote angiogenesis, neurogenesis, and axonal growth, which contribute to tissue repair and functional recovery after SCI [ 109 , 110 ]. In preclinical studies, MSC transplantation has been shown to promote functional recovery and tissue repair after SCI, by reducing the lesion size, preserving myelin, and promoting axonal regeneration [ 111 , 112 ]. Additionally, MSCs are relatively easy to isolate and expand in vitro, making them a more accessible source of stem cells for therapeutic applications.…”

Section: The Potential Of Different Stem Cell Typesmentioning

confidence: 99%

Advancing Spinal Cord Injury Treatment through Stem Cell Therapy: A Comprehensive Review of Cell Types, Challenges, and Emerging Technologies in Regenerative Medicine

Zeng

2023

IJMS

View full text Add to dashboard Cite

Spinal cord injuries (SCIs) can lead to significant neurological deficits and lifelong disability, with far-reaching physical, psychological, and economic consequences for affected individuals and their families. Current treatments for SCIs are limited in their ability to restore function, and there is a pressing need for innovative therapeutic approaches. Stem cell therapy has emerged as a promising strategy to promote the regeneration and repair of damaged neural tissue following SCIs. This review article comprehensively discusses the potential of different stem cell types, such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem/progenitor cells (NSPCs), in SCI treatment. We provide an in-depth analysis of the unique advantages and challenges associated with each stem cell type, as well as the latest advancements in the field. Furthermore, we address the critical challenges faced in stem cell therapy for SCIs, including safety concerns, ethical considerations, standardization of protocols, optimization of transplantation parameters, and the development of effective outcome measures. We also discuss the integration of novel technologies such as gene editing, biomaterials, and tissue engineering to enhance the therapeutic potential of stem cells. The article concludes by emphasizing the importance of collaborative efforts among various stakeholders in the scientific community, including researchers, clinicians, bioengineers, industry partners, and patients, to overcome these challenges and realize the full potential of stem cell therapy for SCI patients. By fostering such collaborations and advancing our understanding of stem cell biology and regenerative medicine, we can pave the way for the development of groundbreaking therapies that improve the lives of those affected by SCIs.

show abstract

Multiple strategies enhance the efficacy of MSCs transplantation for spinal cord injury

Cited by 11 publications

References 167 publications

Injectable hydrogel-based combination therapy for myocardial infarction: a systematic review and Meta-analysis of preclinical trials

Injectable hydrogel-based combination therapy for myocardial infarction: a systematic review and Meta-analysis of preclinical trials

Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury

Advancing Spinal Cord Injury Treatment through Stem Cell Therapy: A Comprehensive Review of Cell Types, Challenges, and Emerging Technologies in Regenerative Medicine

Contact Info

Product

Resources

About